• In recent days, Bristol-Myers Squibb has drawn attention as analysts revised earnings expectations, a partner sought approval for an Opdivo combination therapy, and the company expanded its use of advanced AI and R&D capabilities.
• This combination of pipeline progress, technology investment, and updated forecasts adds fresh context to how investors may view Bristol-Myers Squibb’s longer-term profile.
• We’ll now examine how the Opdivo combination filing and AI-enabled R&D expansion could influence Bristol-Myers Squibb’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol-Myers Squibb today, you need to believe that its growing pipeline, AI-enabled R&D push, and partnerships can gradually backfill pressure from patent expirations and pricing reforms. The recent Opdivo combination filing and AI/R&D expansion do not appear to change the near term focus on upcoming earnings and how quickly newer launches and late stage assets can offset concentration in Eliquis, Opdivo and other key brands.

Among the latest developments, the company’s broader use of Nvidia AI systems and a new San Diego R&D hub stands out alongside the Opdivo combination story. Together, they highlight how Bristol-Myers Squibb is trying to improve drug discovery productivity and support future cash flows, which matters for how investors weigh patent cliff risk against the potential of oncology, cell therapy and immunology assets already moving through the clinic.

Yet while recent news has been encouraging, investors should still be aware that...

Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This implies a 6.2% yearly revenue decline and an earnings increase of about $1.3 billion from $7.3 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts see a very different picture, assuming revenues fall toward about US$37.4 billion by 2029 and earnings only reach roughly US$8.1 billion, which is far more pessimistic than the baseline view and may or may not be adjusted once the Opdivo and AI developments are fully reflected in their models.

Explore 8 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 25% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.